about
Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.Universal Human Papillomavirus Typing Assay: Whole-Genome Sequencing following Target EnrichmentPerformance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.Carcinogenic human papillomavirus infection.Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women.Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers.Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
P2860
Q30239987-F29BA930-A42E-4383-9195-B3278798D9D1Q36224151-38D73894-3284-4AD9-8680-369D05DB3726Q39177983-3F12C9AF-BC5F-4433-9E3A-D26A6A78002FQ44863515-134A8C27-68C4-4BC7-835E-78C77CD384E6Q47319540-C7652445-8952-437A-B5FE-58923E383469Q47572365-54BC8D8B-B83D-4FF7-81CD-ACD0AE8AF927Q47669409-1C1BF350-9AD4-4DD0-B49A-8F4F69A96E8C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@en
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@nl
type
label
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@en
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@nl
prefLabel
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@en
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@nl
P2093
P2860
P356
P1476
Evaluating HPV-negative CIN2+ in the ATHENA trial.
@en
P2093
Catherine M Behrens
J Thomas Cox
Karl Ulrich Petry
Kristin Johnson
Mario Sideri
Ruediger Ridder
Thomas C Wright
P2860
P304
P356
10.1002/IJC.30032
P577
2016-02-06T00:00:00Z